Vaxart, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VXRT research report →
Companyvaxart.com
Vaxart, Inc. , a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.
- CEO
- Steven Lo
- IPO
- 1981
- Employees
- 105
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $142.79M
- P/E
- 3.83
- P/S
- 0.56
- P/B
- 1.51
- EV/EBITDA
- 2.11
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- 14.94%
- Net Margin
- 14.51%
- ROE
- 61.43%
- ROIC
- 34.88%
Growth & Income
- Revenue
- $237.26M · 726.68%
- Net Income
- $16.33M · 124.39%
- EPS
- $0.07 · 150.00%
- Op Income
- $18.07M
- FCF YoY
- 116.70%
Performance & Tape
- 52W High
- $0.84
- 52W Low
- $0.26
- 50D MA
- $0.69
- 200D MA
- $0.51
- Beta
- 1.18
- Avg Volume
- 516.84K
Get TickerSpark's AI analysis on VXRT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 23, 26 | BREITMEYER JAMES B | other | 157,400 |
| Apr 23, 26 | BREITMEYER JAMES B | other | 78,800 |
| Apr 23, 26 | BREITMEYER JAMES B | other | 0 |
| Mar 28, 26 | Tucker Sean | other | 3,924 |
| Mar 28, 26 | Cummings James F. | other | 3,292 |
| Mar 24, 26 | Berg Edward B | other | 36,418 |
| Mar 24, 26 | Cummings James F. | other | 30,551 |
| Mar 24, 26 | Lo Steven | other | 126,028 |
| Mar 24, 26 | Tucker Sean | other | 36,418 |
| Mar 18, 26 | Berg Edward B | other | 8,072 |
Our VXRT Coverage
We haven't published any research on VXRT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VXRT Report →